Cargando…

Clinical effects of cardiac contractility modulation in heart failure with mildly reduced systolic function

AIMS: Increasing attention is being given to patients with heart failure and ‘mid‐range’ left ventricular ejection fraction (LVEF, ≥40% and <50%) for whom there are no approved therapies that improve prognosis. We aim to assess for the first time the effects of cardiac contractility modulation (C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tschöpe, Carsten, Butler, Javed, Farmakis, Dimitrios, Morley, Deborah, Rao, Ishu, Filippatos, Gerasimos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754749/ https://www.ncbi.nlm.nih.gov/pubmed/33274601 http://dx.doi.org/10.1002/ehf2.13126

Ejemplares similares

Drug therapy for patients with systolic heart failure after the PARADIGM-HF trial: in need of a new paradigm of LCZ696 implementation in clinical practice
por: Filippatos, Gerasimos, et al.
Publicado: (2015)

Cardiac contractility modulation therapy improves health status in patients with heart failure with preserved ejection fraction: a pilot study (CCM‐HFpEF)
por: Linde, Cecilia, et al.
Publicado: (2022)

Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: a secondary analysis of EMPEROR‐Reduced
por: Filippatos, Gerasimos, et al.
Publicado: (2022)

Cardiac contractility modulation: mechanisms of action in heart failure with reduced ejection fraction and beyond
por: Tschöpe, Carsten, et al.
Publicado: (2018)

Long‐term clinical experience with cardiac contractility modulation therapy delivered by the Optimizer Smart system
por: Kuschyk, Jürgen, et al.
Publicado: (2021)

Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes
por: Filippatos, Gerasimos, et al.
Publicado: (2022)

Cancer and Takotsubo syndrome: from rarity to clinical practice
por: Keramida, Kalliopi, et al.
Publicado: (2021)

Genetic Predisposition to Cardiovascular Disease in Patients With Cancer: A Clinical Perspective
por: Farmakis, Dimitrios, et al.
Publicado: (2023)

Heart Failure 2012
por: Giamouzis, Gregory, et al.
Publicado: (2012)

Effects of Cardiac Contractility Modulation Electrodes on Tricuspid Regurgitation in Patients with Heart Failure with Reduced Ejection Fraction: A Pilot Study
por: Masarone, Daniele, et al.
Publicado: (2022)

Totality of evidence in trials of sodium–glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction: implications for clinical practice
por: Butler, Javed, et al.
Publicado: (2020)

Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis
por: Filippatos, Gerasimos, et al.
Publicado: (2023)

Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced
por: Zannad, Faiez, et al.
Publicado: (2020)

Breakthroughs in the treatment of heart failure with mildly reduced and preserved ejection fraction
por: Talha, Khawaja M., et al.
Publicado: (2022)

Clinical effects of long-term cardiac contractility modulation (CCM) in subjects with heart failure caused by left ventricular systolic dysfunction
por: Müller, D., et al.
Publicado: (2017)

Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR‐Reduced
por: Ferreira, João Pedro, et al.
Publicado: (2022)

Concentration‐dependent clinical and prognostic importance of high‐sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the EMPEROR‐Reduced trial
por: Packer, Milton, et al.
Publicado: (2021)

Heart failure guidelines implementation: Lifting barriers using registries and networks
por: Keramida, Kalliopi, et al.
Publicado: (2020)

Heterogeneous responses of systolic and diastolic left ventricular function to exercise in patients with heart failure and preserved ejection fraction
por: Kasner, Mario, et al.
Publicado: (2015)

Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms
por: Lee, Dawn, et al.
Publicado: (2014)

Clinical development plan for regenerative therapy in heart failure
por: Terzic, Andre, et al.
Publicado: (2016)

Cardiac Amyloidosis Presenting as Biventricular Systolic Heart Failure
por: Oye, Monique, et al.
Publicado: (2021)

The Impact of Bronchodilator Therapy on Systolic Heart Failure with Concomitant Mild to Moderate COPD
por: Kato, Mahoto, et al.
Publicado: (2017)

Galectin-3 and fibulin-1 in systolic heart failure - relation to glucose metabolism and left ventricular contractile reserve
por: Holmager, Pernille, et al.
Publicado: (2017)

Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction
por: Butler, Javed, et al.
Publicado: (2021)

Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial( )
por: Doehner, Wolfram, et al.
Publicado: (2022)

Advances in systolic heart failure
por: Yuzefpolskaya, Melana, et al.
Publicado: (2010)

Echocardiographic Assessment of Pulmonary Artery Systolic Pressure and Outcomes in Ambulatory Heart Failure Patients
por: Kalogeropoulos, Andreas P., et al.
Publicado: (2014)

Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta‐analysis
por: Butler, Javed, et al.
Publicado: (2020)

Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure
por: Packer, Milton, et al.
Publicado: (2023)

Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial
por: Filippatos, Gerasimos, et al.
Publicado: (2014)

Inflammation – Cause or Consequence of Heart Failure or Both?
por: Van Linthout, Sophie, et al.
Publicado: (2017)

Cardiac contractility modulation: a novel approach for the treatment of heart failure
por: Abi-Samra, Freddy, et al.
Publicado: (2016)

Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR‐Reduced
por: Anker, Stefan D., et al.
Publicado: (2022)

Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure: A Secondary Analysis of EMPEROR-Pooled
por: Ferreira, João Pedro, et al.
Publicado: (2022)

Outcomes with empagliflozin in heart failure with preserved ejection fraction using DELIVER‐like endpoint definitions
por: Anker, Stefan D., et al.
Publicado: (2022)

Systolic heart failure and cardiac resynchronization therapy: a focus on diastole
por: Facchini, Emanuela, et al.
Publicado: (2014)

Cost-effectiveness of implantable cardiac devices in patients with systolic heart failure
por: Mealing, Stuart, et al.
Publicado: (2016)

Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO‐DKD trial
por: Filippatos, Gerasimos, et al.
Publicado: (2022)

Heart Failure 2013
por: Giamouzis, Gregory, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_02q8ce15ctvoh0hv15c45q9dsn